Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2011;6(10):e25725. doi: 10.1371/journal.pone.0025725. Epub 2011 Oct 3.

Effect of sulindac sulfide on metallohydrolases in the human colon cancer cell line HT-29.

Author information

  • 1WM Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, United States of America.

Abstract

Matrix metalloproteinase 7 (MMP7), a metallohydrolase involved in the development of several cancers, is downregulated in the Apc(Min/+) colon cancer mouse model following sulindac treatment. To determine whether this effect is relevant to the human condition, HT-29 human colon cancer cells were treated with sulindac and its metabolites, and compared to results obtained from in vivo mouse studies. The expression of MMP7 was monitored. The results demonstrated that sulindac sulfide effectively downregulated both MMP7 expression and activity. Furthermore, activity-based proteomics demonstrated that sulindac sulfide dramatically decreased the activity of leukotriene A4 hydrolase in HT-29 cells as reflected by a decrease in the level of its product, leukotriene B4. This study demonstrates that the effect of sulindac treatment in a mouse model of colon cancer may be relevant to the human counterpart and highlights the effect of sulindac treatment on metallohydrolases.

PMID:
21991341
[PubMed - indexed for MEDLINE]
PMCID:
PMC3185020
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk